PARP1 and cancer: PARP inhibitors such as olaparib, niraparib, rucaparib, and talazoparib are currently being used to treat various cancers (Del Campo et al, 2019; Matulonis et al, 2016; Moore et al, 2018; Swisher et al, 2017), and the natural product nimbolide has been shown to target RNF114, preventing its ubiquitylation and degradation of PARP1 (Li et al, 2023).